ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(FRX)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; Teflaro for the treatment of adults with skin and skin structure infections, and community-acquired bacterial pneumonia; Daliresp to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD; and Viibryd for the treatment of adults with major depressive disorder (MDD). The company has products under new drug application review by Food and Drug Administration comprising Aclidinium for the maintenance treatment of COPD; and Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. It also develops ceftaroline/avibactam combination, which is under Phase III clinical trials for complicated intra-abdominal infections, as well as has completed Phase II clinical trials for complicated urinary tract infections; and Cariprazine that is in Phase III clinical trials for the treatment of acute exacerbation of schizophrenia and acute mania associated with bipolar disorder. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; GRT 6005 that is under Phase II clinical trials for nociceptive and neuropathic pain; TTP399, which is under Phase II clinical trials for the treatment of Type II diabetes; and RGH-618 that is under Phase I clinical trials for the treatment of anxiety, depression, and other central nervous system conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. The company was founded in 1956 and is headquartered in New York, New York.

Recent News: